Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Viking Therapeutics in a research note issued to ...
Investment analysts at Leerink Partnrs increased their FY2024 earnings per share (EPS) estimates for Tourmaline Bio in a ...
U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...
After a rough 2024, Teladoc Health (TDOC) has seen its shares surge up roughly 45% year-to-date, catalyzed by a recent ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 45th Annual Health Care Conference at 11:50 a.m. ET on Tuesday, March 4, 2025Leerink Partners ...
It reported a medical loss ratio - a percentage of premiums spent on medical care - at a record high of 95.2% in October, as ...
Leerink Partners made a slight adjustment to the price target of Inspire Medical Systems (NYSE:INSP), raising it from $193.00 to $194.00, while keeping a Market Perform rating on the stock. According ...
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price ...
In a turbulent market environment, Alto Neuroscience's stock (ANRO) has recorded a new 52-week low, dipping to $3.23, marking a stark contrast to its 52-week high of $18.35. According to InvestingPro ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results